# Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

> **NCT02201771** · PHASE4 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 500 (actual)

## Conditions studied

- Coronary Artery Bypass
- Antiplatelet Agents

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT02201771
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201771, "Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02201771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*